To support the hypothesis that SFN affects the biological behavior of HCC cells by activating Wnt/β-catenin signaling, we further verified this hypothesis by treating SFN-overexpressing cells (SMMC-7721-Lv-SFN) with the Wnt signaling pathway-specific antagonist XAV-939. This evidence concerns the gene SFN and hepatocellular carcinoma.